Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady

Moderna's personalized melanoma vaccine cleared its primary hurdle in a late-stage trial, yet shares are sinking fast. The gap between what the data promised and what it delivered is forcing traders to rethink how much the company's flagship cancer bet is actually worth.